Ardian acquires 60% stake in Dedalus founder Giorgio Moretti retains 40% and continues to lead the company

This is the sixth deal executed by the Ardian Mid Cap Buyout team in Italy.

Over the years, thanks to a targeted acquisition strategy, which has resulted in 40 companies being acquired, and important investments in Research & Development, Dedalus has become an international company and an established leader in its field. Following the merger with NoemaLife, of which Dedalus recently acquired more than 83%, the company will become the leading player in clinical health software in Italy and one of the biggest in Europe, with a global reach across 25 countries. The Group expects to close 2016 with a turnover of approximately 170 million euro.

Last June 28th 2016, Dedalus announced the acquisition of the majority of NoemaLife that involves the promotion of a Mandatory Public Tender Offer of 1,339,472 ordinary shares of NoemaLife S.p.A., listed on the Borsa Italiana's Main Market (MTA)with a price of €7.40 per share. At the same time Dedalus will also promote the Voluntary Offer on Warrants of NoemaLife, at a price of €0.423 for each Warrant.

Following the merger with NoemaLife, Ardian will support Dedalus in the company’s international growth, with the intention to invest in innovation and enhancing its ability to service customers.

Yann Chareton, Managing Director, Ardian Mid Cap Buyout, said: “Dedalus is an Italian luminary that offers interesting growth opportunities even after the recent acquisition of NoemaLife. Wewill work along with Giorgio Moretti and his management team to explore new avenues of business development and to attain an even stronger position in the clinical health sector at an international level. The great work done so far by Dedalus will be further developed by our long-term investment approach, which will aim to fully exploit the group’s skills and expertise."

Giorgio Moretti, Chairman and CEO of Dedalus, added: ”The ICT sector in the clinical health industry in the coming years will inexorably face an important global consolidation process, certainly in Europe. Investments in R&D to maintain competitiveness and new business models that need significant initial investment all require important financial resources, a large customer base and a strong international presence. After a careful evaluation of the potential partners that showed interest in our plan, we felt Ardian the most suitable for supporting us in the challenges we face on a global scale. This is thanks to the expertise of its managers, their ability to understand our business and the speed with which they could complete this transaction. We would like to thank the funds that have supported us this far: Mandarin Cp and Hutton Collins. We shared an exciting path in recent years, thanks to which we could realize the NoemaLife deal.”